ATS 2022
TRAVERSE Trial of Dupilumab for Severe Oral Corticosteroid-Dependent Asthma
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Your search for oral corticosteroids returned 12 results
CHEST 2022
Dupilumab Reduces Oral Corticosteroid Use in OCS-Dependent Severe Asthma
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
CHEST 2022
ICS-LABA Proved Effective in Treating Sjogren Syndrome With Bronchiolitis
Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.
ACAAI 2022
Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma
The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.
AAAAI 2022
Escalation to Biologics in Asthma: The Role of Suboptimal Treatment Adherence
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
AAAAI 2022
Azithromycin and Recurrent Wheeze in Children After Severe RSV Bronchiolitis
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
ACAAI 2022
Uncontrolled Asthma in Hispanic/Latino Patients Improved With Tezepelumab
Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.
CHEST 2022
Tezepelumab Improves Severe Asthma Even in Those Using Multiple Controllers
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
CHEST 2022
Tezepelumab Improves Severe Asthma Even in Those Using Multiple Controllers
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
ATS Virtual Program 2020
Low-Severity COPD: Risk for Exacerbation, Hospitalization, and Death
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
